191 related articles for article (PubMed ID: 22017448)
1. Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.
Lisi L; Tramutola A; De Luca A; Navarra P; Dello Russo C
J Neurochem; 2012 Jan; 120(1):106-14. PubMed ID: 22017448
[TBL] [Abstract][Full Text] [Related]
2. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
3. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
4. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis.
Bruno R; Galastri S; Sacchi P; Cima S; Caligiuri A; DeFranco R; Milani S; Gessani S; Fantuzzi L; Liotta F; Frosali F; Antonucci G; Pinzani M; Marra F
Gut; 2010 Apr; 59(4):513-20. PubMed ID: 19736361
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein.
Ronaldson PT; Bendayan R
Mol Pharmacol; 2006 Sep; 70(3):1087-98. PubMed ID: 16790532
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
Cipriani S; Francisci D; Mencarelli A; Renga B; Schiaroli E; D'Amore C; Baldelli F; Fiorucci S
Circulation; 2013 May; 127(21):2114-24. PubMed ID: 23633271
[TBL] [Abstract][Full Text] [Related]
7. In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
Gramegna P; Latronico T; Branà MT; Di Bari G; Mengoni F; Belvisi V; Mascellino MT; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
PLoS One; 2011; 6(12):e28499. PubMed ID: 22174822
[TBL] [Abstract][Full Text] [Related]
8. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
11. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral agents increase NO production in gp120/IFNγ-stimulated cultures of rat microglia via an arginase-dependent mechanism.
Lisi L; Tramutola A; Navarra P; Dello Russo C
J Neuroimmunol; 2014 Jan; 266(1-2):24-32. PubMed ID: 24268674
[TBL] [Abstract][Full Text] [Related]
13. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
Flynn JK; Paukovics G; Moore MS; Ellett A; Gray LR; Duncan R; Salimi H; Jubb B; Westby M; Purcell DF; Lewin SR; Lee B; Churchill MJ; Gorry PR; Roche M
Virology; 2013 Jul; 442(1):51-8. PubMed ID: 23602007
[TBL] [Abstract][Full Text] [Related]
14. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
Soulié C; Malet I; Lambert-Niclot S; Tubiana R; Thévenin M; Simon A; Murphy R; Katlama C; Calvez V; Marcelin AG
AIDS; 2008 Oct; 22(16):2212-4. PubMed ID: 18832886
[TBL] [Abstract][Full Text] [Related]
15. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
17. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
Espirito-Santo M; Santos-Costa Q; Calado M; Dorr P; Azevedo-Pereira JM
AIDS Res Hum Retroviruses; 2012 May; 28(5):478-85. PubMed ID: 21902586
[TBL] [Abstract][Full Text] [Related]
19. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
20. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120.
Giunta B; Ehrhart J; Townsend K; Sun N; Vendrame M; Shytle D; Tan J; Fernandez F
Brain Res Bull; 2004 Aug; 64(2):165-70. PubMed ID: 15342104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
